Dubai, 10 May 2016: Diabetes is becoming a growing health concern in the UAE, due to higher levels of obesity compared to other countries in the region. As major pharmaceuticals and healthcare institutions work towards combating this problem, another concern as risen. A recent survey conducted for AstraZeneca has shown that Diabetic patients in the UAE are not taking their medicines, which can lead to a host of additional complications. Providentially, Al Ittihad Drug Store (IDS), one of the UAE’s biggest pharmaceutical distributors is proposing a solution to this problem with its recently introduced Insupen 33G X 4mm from its Pic Diabetes Care range. The Pic Diabetes Care range provides simple and innovative solutions to help manage Insulin dependent diabetes patients and improve their quality of life. Insupen is based on technologies that meet all the quality standards with every feature designed to allow a pain-free injection. IDS has always championed and empowered Pic’s commitment to technological research which has led them to create some of the best needles in the market. Since the pain associated with injection and the fear of needles are major obstacles for Diabetic patients, influencing their acceptance and adherence to therapy, needles of progressively smaller length and guage have been recommended and subsequently developed. The latest Pic needles are extremely thin, helping reduce skin trauma and pain, while their internal lumen optimises the insulin flow. “Our goal at IDS is to increase the overall quality of life of UAE residents and this is reflected in our wide range of product portfolio including Insupen. We were the first to launch a 32G pen needle in 2007 which was the inspiration for Insupen 33G X 4mm. We are confident that this device from the Pic Diabetes Care range will add value to the lives of Diabetic patients and make it easier for them to treat themselves” Said Dalya Tabari, Director Al Ittihad Drug Store (IDS). Al Ittihad Drug Store (IDS) is one of the leading distributors in the UAE with a turnover exceeding AED 300 million in 2015. During the last ten years, IDS has shown pronounced growth in every category, including growing yearly revenues, market share, number of prescriptions, product portfolio, and representing international partners. For more information, visit www.ids.ae.
|